Efficacy and safety of solifenacin succinate in Korean patients with overactive bladder: A randomised, prospective, double-blind, multicentre study

International Journal of Clinical Practice

Volumn 62, Issue 11, 2008, Pages 1675-1683

  Choo, M S ^a   Lee, J Z ^b   Lee, J B ^c   Kim, Y H ^d   Jung, H C ^e   Lee, K S ^f   Kim, J C ^g   Seo, J T ^h   Paick, J S ⁱ   Kim, H J ^j   Na, Y G ^k   Lee, J G ^l,m  

^a University of Ulsan College of Medicine   (South Korea)

^b Pusan National University School of Medicine   (South Korea)

^c National Medical Center   (South Korea)

^d Soonchunhyang University   (South Korea)

^e Young Nam University Hospital   (South Korea)

^f Sungkyunkwan University School of Medicine   (South Korea)

^g The Catholic University of Korea   (South Korea)

^h Kwandong University College of Medicine   (South Korea)

ⁱ Seoul National University College of Medicine   (South Korea)

^j Dankook University College of Medicine   (South Korea)

^k Chungnam National University College of Medicine   (South Korea)

^l Korea University College of Medicine   (South Korea)

^m Korea University College of Medicine   (South Korea)

more..

Author keywords

[No Author keywords available]

Indexed keywords

SOLIFENACIN; TOLTERODINE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BLURRED VISION; CLINICAL TRIAL; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTITIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRY EYE; DYSPEPSIA; FEMALE; HUMAN; INCIDENCE; INTOXICATION; KOREA; MAJOR CLINICAL STUDY; MALE; MICTURITION; MICTURITION DISORDER; MULTICENTER STUDY; NERVOUS SYSTEM INJURY; NOCTURIA; OUTCOME ASSESSMENT; OVERACTIVE BLADDER; POPULATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; RHINOPHARYNGITIS; SIDE EFFECT; SKIN DISEASE; SYMPTOM; URINARY DYSFUNCTION; URINARY FREQUENCY; URINARY URGENCY; VESICAL TENESMUS; XEROSTOMIA;

ADULT; AGED; AGED, 80 AND OVER; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; NOCTURIA; PATIENT SATISFACTION; PROSPECTIVE STUDIES; QUINUCLIDINES; TETRAHYDROISOQUINOLINES; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE; URINARY RETENTION;

EID: 54049150815     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2008.01898.x     Document Type: Article

References (22)

1. Abrams P, Cardozo L, Fall M et al. The standardisation of terminology in lower urinary tract function: report from the Standardisation Sub-Committee of the International Continence Society. Urology 2003 61 : 37 49.
2. Milsom I, Stewart W, Thuroff J. The prevalence of overactive bladder. Am J Manag Care 2000 11 (Suppl. S565 73.
3. Chapple CR. Muscarinic receptor antagonists in the treatment of overactive bladder. Urology 2000 55 (Suppl. 5A 33 46.
4. Appell RA, Sand P, Dmochowski R et al. Overactive Bladder: Judging Effective Control and Treatment Study Group. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin Proc 2001 76 : 358 63.
5. Kelleher CJ, Cardozo LD, Khullar V et al. A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. Br J Obstet Gynaecol 1997 104 : 988 93.
6. Ikeda K, Kobayashi S, Suzuki M et al. M3 receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naun-Schmied Arch Pharmacol 2002 366 : 97 103.
7. Chapple CR, Arano P, Bosch JL et al. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU Int 2004 93 : 71 7.
8. Cardozo L. Randomized, double-blind placebo-controlled trial of once-daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004 172 : 1919 24.
9. Chapple CR, Rechberger T, Al-Shukri S et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int. 2004 93 : 303 10.
10. Chapple CR, Martinez-Garcia R, Selvaggi L et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005 48 : 464 70.
11. Chapple CR, Fianu-Jonsson A, Indig M et al. Treatment outcomes in the STAR study: a subanalysis of solifenacin 5 mg and tolterodine ER 4 mg. Eur Urol 2007 52 : 1195 203.
12. Haab F, Cardozo L, Chapple C et al. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol 2005 47 : 376 84.
13. Kelleher CJ, Cardozo LD, Khullar V et al. A new questionnaire to assess the quality of life of urinary incontinence in women. Br J Obstet Gynecol 1997 104 : 1374 9.
14. Oh SJ, Park HG, Paick SH et al. Translation and linguistic validation of Korean version of the King's Health Questionnaire instrument. The Korean Journal of Urology 2005 46 : 438 50.
15. Herbison P, Hay-Smith J, Ellis G et al. Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. BMJ 2003 326 : 841 8.
16. Landis RJ, Kaplan S, Swift S et al. Efficacy of antimuscarinic therapy for overactive bladder with varying degree of incontinence severity. J Urol 2004 171 : 752 6.
17. Yamaguchi O, Marui E, Kakizaki H et al. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. BJU Int 2007 100 : 579 87.
18. Versi E, Appell R, Mobley D et al. Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. Obstet Gynecol 2000 95 : 718 21.
19. Diokno AC, Appell RA, Sand PK et al. for the OPERA Trial. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA Trial. Mayo Clin Proc 2003 78 : 687 95.
20. Hatanaka T, Ukai M, Ohtake A et al. In Vitro Tissue Selectivity Profile of Solifenacin Succinate (YM905) for Urinary Bladder Over Salivary Gland in Rats and Monkeys. Florence : International Continence Society Meeting, 2003, abstract 3.
21. Smulders RA, Van Alphen WW, Visser JN et al. Multiple Dosing With YM905, a Novel, Bladder-Selective Antimuscarinic, in Healthy men: Safety, Tolerability, and Pharmacokinetics. Heidelberg : International Continence Society Meeting, 2002, abstract 439.
22. Kelleher CJ, Cardozo L, Chapple CR et al. Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU Int 2005 95 : 81 5.